© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.

Slides:

Advertisements

Similar presentations

Technology Management Activities and Tools

Advertisements

CONTINUOUS QUALITY VERIFICATION (CQV) G. K. Raju, Ph. D

The ACPS’s Process Analytical Technology Subcommittee

Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.

Canada/Australia Issues being faced in the regulation of nano-materials Deborah Willcocks – Department of Health and Ageing, Government of Australia Anne-Marie.

Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

Project title Your Names Plan on 8 minutes (no more than 6 slides)

What Do Toxicologists Do?

Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Ray Scherzer FDA ACPS October 26, 2005 Breaking with Tradition: The Manufacturing Challenges Ahead!

Global Quality Operations

MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.

LIFE SCIENCES Pharmaceutical Manufacturing Chemical & Biosciences Technology QA/QC in Pharmaceutical Industry Applied Biology & Chemistry.

CURRENT PHARMACEUTICAL MARKETING STRATEGY M.ABHINANDANA M.PHARM Q.A.

Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

Quality By Design and Dissolution PhRMA 10/25/05

Outline Thought for the day! Acknowledgements Top issues

Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

PQRI Work Project Concept Fundamental Understanding of Sulfonate Ester-Forming Reactions April 2006.

1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.

The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development

1 Cross Labeling Combination Products Bradley Merrill Thompson, MBA, JD, RAC Epstein Becker & Green PC.

Total Excipient Control (TEC) Tools for Managing Excipient Quality A Pathway to Increased Patient Safety David R. Schoneker Vice Chair – Maker and Distributor.

1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Opening Remarks Ajaz S. Hussain, Ph.D.

Chris Charalambous BSc (Hons) Biotechnology Master of Management (Research)

Small molecules Liquids – Solvent composition – Reactions – HME Dry Powder – Blending – Dry Granulation – Dry milling Wet solids – API Crystallization.

Purdue University – Industrial and Physical Pharmacy - Morris Discussion Questions of Polymorphism in ANDAs Ken Morris Industrial and Physical Pharmacy.

Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,

Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.

10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.

Biotechnology. D Biotechnology2 Definition Techniques used to modify deoxyribonucleic acid (DNA) or the genetic material of a microorganism, plant,

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute.

1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.

Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

开发报批美国 FDA 的仿制药与相关问题探讨上海复星普适医药科技有限公司何平. 内容提要开发仿制药的重要性和机遇开发仿制药的重要性和机遇开发仿制药的挑战开发仿制药的挑战申报仿制药的分类申报仿制药的分类仿制药研发团队仿制药研发团队仿制药的研发过程仿制药的研发过程 QbD 在制剂开发中怎么体现.

QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.

INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.

QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.

© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.

PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1.

An Update on ICH Guideline – Pharmaceutical Development

Pharmaceutical Quality in the 21st Century

Quality System.

QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.

Chapter 1 What is Biotechnology.

Presentation transcript:

© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING” l “Manufacturing” (derived from Latin) = “manus” (hand) + “factus” (made) = “made by hand” l “Manufacturing” is the transformation of materials and information into goods for the satisfaction of human needs Material Information

© G.K.Raju, Ph.D. Manufacturing Science “SCIENCE” l A body of knowledge, body of facts or information, body of laws or principles, body of truths, or verities or realities…… l Skill, expertise, mastery, know-how l Organized knowledge l A means of solving problems.. The Synonym Finder J. I. Rodale

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” “Manufacturing”“Science” “ Manufacturing Science” A body of knowledge, body of facts or information, body of laws or principles, body of truths, or verities or realities…… Transformation of materials and information into goods for the satisfaction of human needs

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: A DEFINITION Body of Knowledge, Laws, Principles Involved In The Transformation of Materials and Information into Goods for the Satisfaction of Human Needs

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DIMENSIONS Body of Knowledge, Laws, Principles Involved In The Transformation of Materials and Information into Goods for the Satisfaction of Human Needs Extent Of Mfg. Science

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : Levels of Knowledge Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, …

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DIMENSIONS Body of Knowledge, Laws, Principles Involved In The Transformation of Materials and Information into Goods for the Satisfaction of Human Needs Extent Of Mfg. Science

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: The “Time” Dimension THE DESIRED STATE Extent Of Mfg. Science Time “Right First Time” LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DESIRED RELATIVE TO CURRENT STATE (Personal Opinion) Extent Of Mfg. Science Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SYSTEM” A “manufacturing system” is set of processes and systems (and people) bound by a common material and information flow. Material Information WEIGH WET GRANULN STEPFB DRY STEP BLEND ENCAPSULATE SIEVE QC 1 QC 3 QC 4 DRY MIX QC 2

© G.K.Raju, Ph.D. Manufacturing Science ACTIVE FORMULNFILL PACK ACTIVE FORMULNFILLPACK ACTIVE FORMULNFILLPACK RESEARCH DEVELOPMENT MANUFACTURING TIME SPACE PHARMACEUTICAL MANUFACTURING SYSTEM COST QUALITY TIME SAFETY

© G.K.Raju, Ph.D. Manufacturing Science PROCESS A WITH QC TESTS WEIGHING WET GRANULATION STEPFB DRY STEP BLEND ENCAPSULATESIEVE API MICRO Particle Size Description ID Assay CU Impurity Dissolution MICRO QC 1 QC 3 QC 4 DRY MIX QC 2 LOD

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : Levels and Focus Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, …

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DESIRED RELATIVE TO CURRENT STATE (Personal Opinion) Extent Of Mfg. Science Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science Food & Drug Administration: August 21 st 2002 The FDA Announced today that the Agency will be undertaking a Significant new initiative concerning the regulation of pharmaceutical Manufacturing and product quality. The initiative, Pharmaceutical cGMPs for the 21 st Century: A Risk Based Approach… -- Lester Crawford FDA Deputy Commissioner Pharmaceutical cGMPs Initiative

© G.K.Raju, Ph.D. Manufacturing Science US FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science U.S. FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science PROCESS A WITH QC TESTS WEIGHING WET GRANULATION STEPFB DRY STEP BLEND ENCAPSULATESIEVE API MICRO Particle Size Description ID Assay CU Impurity Dissolution MICRO QC 1 QC 3 QC 4 DRY MIX QC 2 LOD

© G.K.Raju, Ph.D. Manufacturing Science FDA PAT Initiative The FDA Process Analytical Technologies (PAT) Initiative Is An Effort To Facilitate The Introduction of New Technologies To The Manufacturing Sector Of The Pharmaceutical Industry

© G.K.Raju, Ph.D. Manufacturing Science CYCLE TIME COMPONENTS

© G.K.Raju, Ph.D. Manufacturing Science ON-LINE TECHNOLOGY IMPACTS DOMINANT CYCLE TIMES On-line LIF, NIR, Pattern Recognition, etc.

© G.K.Raju, Ph.D. Manufacturing Science ACTIVE FORMULNFILL PACK ACTIVE FORMULNFILLPACK ACTIVE FORMULNFILLPACK RESEARCH DEVELOPMENT MANUFACTURING TIME SPACE Which Products? High Volume Complex Liquid Blending Drying Granulation Flow Tableting Transport Assay Fermentation Rapid Microbial Detection 10% 5% 1% 0.5% 0.1% PHARMACEUTICAL MANUFACTURING: The PAT Opportunity..

© G.K.Raju, Ph.D. Manufacturing Science U.S. FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : IMPLICATIONS Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, … FDA

© G.K.Raju, Ph.D. Manufacturing Science U.S. FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : Levels of Knowledge Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, …

© G.K.Raju, Ph.D. Manufacturing Science US FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science APPROACH TO LEARNING: Current ApproachProposed Approach x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x xx x x xxx x x x x x x x x x x x x x x x x x x x x x x x x x xx x x xxx x x x x x x x x Process Development Commercial Production 1a 1b 2a 2b Consequences on Process Development & Commercial Production

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DESIRED RELATIVE TO CURRENT STATE (Personal Opinion) Extent Of Mfg. Science Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science US FDA cGMPs FOR THE 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization

© G.K.Raju, Ph.D. Manufacturing Science Pharmaceutical Manufacturing Research Development Manufacturing Marketing ????

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : Levels of Knowledge Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, …

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : IMPLICATIONS Extent Of Mfg. Science PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, … FDA

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l “MANUFACTURING SCIENCE”: A DEFINITION l “MANUFACTURING SCIENCE”: DIMENSIONS l MANUFACTURING SYSTEM: “HERE” l MANUFACTURING SYSTEM: TO “THERE” l IMPLICATIONS

© G.K.Raju, Ph.D. Manufacturing Science May 21 st 2003 PHARMA MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century G.K.Raju, Ph.D.